Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
The DOI matches its Crossref record.
Abstract
Brief Reports1 July 1992Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic CorrelationsMargaret M. Redfield, MD, Walter J. Nicholson, MD, William D. Edwards, MD, A. Jamil Tajik, MDMargaret M. Redfield, MD, Walter J. Nicholson, MD, William D. Edwards, MD, A. Jamil Tajik, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-117-1-50 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptErgot alkaloid preparations such as ergotamine (Cafergot, Sandoz, East Hanover, New Jersey) and methysergide (Sansert, Sandoz) are used to treat migraine headache. Characteristic histologic changes are seen in patients with methysergide-induced valvular disease (primarily mitral and aortic regurgitation) (1, 2). Recently, ergotamine-induced valvular disease was documented pathologically (3). We report the echocardiographic and pathologic features of five patients with valvular disease associated with long-term ingestion of ergot alkaloids.PatientsCase HistoriesAll patients were using ergot alkaloid preparations for treatment of headache. Patients were initially identified because gross pathologic findings were thought to be unusually severe for rheumatic disease. The...References1. BanaMacNealLeCompteShahGraham DPPYJ. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J. 1974;88:640-55. CrossrefMedlineGoogle Scholar2. Misch K. Development of heart valve lesions during methysergide therapy. Br Med J. 1974;2:365-6. CrossrefMedlineGoogle Scholar3. HauckEdwardsDanielsonMullanyBresnahan AWGCD. Mitral and aortic valve disease associated with ergotamine therapy for migraine: report of two cases and review of literature. Arch Pathol Lab Med. 1990;114:62-4. MedlineGoogle Scholar4. MunroeAllenCox DPA. Mitral regurgitation occurring during methysergide (Sansert) therapy. Can Med Assoc J. 1969;101:62-5. MedlineGoogle Scholar5. MasonBillinghamFriedman JMJ. Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation. 1977;56:889-90. CrossrefMedlineGoogle Scholar6. Spierings E. Cardiac murmurs indicative of aortic valve disease with chronic and excessive intake of ergotamine. Headache. 1988;28:278-9. CrossrefMedlineGoogle Scholar7. SeilerJenzerKàcl KHJ. Verlauf eines Falles von Ergotismus mit Femoralarterienverschlüssen und Mitralinsuffizienz. Vasa. 1973;2:366-71. MedlineGoogle Scholar8. Graham J. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci. 1967;254:1-12. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From Mayo Clinic and Mayo Foundation, Rochester, Minnesota; and Cardiac Diagnostics Associates, York, Pennsylvania. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMitral Regurgitation in Patients Undergoing Noncardiac SurgeryMonitoring patients receiving dopamine agonist therapy for hyperprolactinaemiaPostoperative Management of Patients After Transcatheter Mitral Valve Procedures5-HT2B Receptor on Macrophages: What for?Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter MechanismsValvular Heart Disease: Pathological Anatomy and PathogenesisRheumatic Heart DiseaseMechanotransduction Mechanisms in Mitral Valve Physiology and Disease PathogenesisDrug-Induced Fibrosing LesionsProspective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemiaDrugs That May Cause or Exacerbate Heart FailureThe safety of treatments for prolactinomasValvular Heart DiseaseCarcinoid heart disease: Diagnosis and managementValvular Heart Disease in Patients with Prolactinomas on Cabergoline TreatmentCabergoline Use for Pituitary Tumors and Valvular DisordersInduction of Valvular Heart Disease by Pharmacological InterventionsCardiovascular Toxicity of Noncardiovascular DrugsValvular Heart Disease Associated with Long-term Treatment by Methysergide: a Case ReportSafety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomasCardiac Valve Involvement in Systemic Diseases: A ReviewScientific Opinion on Ergot alkaloids in food and feedNative Cardiac Valve PathologyCardiovascular SystemSupplemental Studies for Cardiovascular Risk Assessment in Safety Pharmacology: A Critical OverviewRegression of Cardiac Valvulopathy Related to Ergot-Derived Dopamine AgonistsSerotonin receptors and heart valve disease—It was meant 2BThe risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonistsAortic valve disease and treatment: The need for naturally engineered solutionsMitral StenosisEvaluation of Tricuspid Regurgitation by Two-Dimensional and Doppler Echocar
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,495
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.007 · Cited by 2,257
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.021 · Cited by 1,702
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Self-citation
Metadata
- Authors
- Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1992-07-01
- Volume
- 117
- Issue
- 1
- Pages
- 50-52
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2073847995
- Cited by
- 156
- References
- 0
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations. https://app.cochat.ai/papers/10.7326/0003-4819-117-1-50
- The paper
- Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992). Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-117-1-50
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.